Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-Analysis
Oral PCSK9 inhibitors demonstrate lipid-lowering efficacy and safety comparable to that of currently approved injectable PCSK9 therapies. These findings support their potential as a convenient and effective alternative, although current evidence remains limited to early-phase studies.
Authors
- Leandro Barbagelata (ORCID: https://orcid.org/0000-0003-3694-1083)
- Martín Lobo (ORCID: https://orcid.org/0000-0003-1377-7313)
- Juan Patricio Nogueira (ORCID: https://orcid.org/0000-0002-8764-4700)
- Walter Massón (ORCID: https://orcid.org/0000-0002-5620-6468)
- Gustavo Giunta (ORCID: https://orcid.org/0000-0002-1913-0310)
Institutions
- Favaloro University (AR)
- Hospital Italiano de Buenos Aires (AR)
- Fundacion Favaloro Hospital Universitario (AR)
- Universidad Internacional de las Américas (CR)
- Servicio Geológico Minero Argentino (AR)
- National University of Formosa (AR)
- Favaloro Foundation (AR)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2025-11-25
- DOI
- https://doi.org/10.1007/s12325-025-03418-x
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00